Compare STEL & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEL | TNGX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | STEL | TNGX |
|---|---|---|
| Price | $32.33 | $9.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $31.33 | $12.50 |
| AVG Volume (30 Days) | 241.2K | ★ 2.7M |
| Earning Date | 01-29-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.94 | N/A |
| Revenue | ★ $416,539,000.00 | $66,501,000.00 |
| Revenue This Year | N/A | $53.01 |
| Revenue Next Year | $3.41 | N/A |
| P/E Ratio | $16.72 | ★ N/A |
| Revenue Growth | N/A | ★ 53.29 |
| 52 Week Low | $24.13 | $1.03 |
| 52 Week High | $32.74 | $11.20 |
| Indicator | STEL | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 63.89 | 49.09 |
| Support Level | $31.46 | $8.89 |
| Resistance Level | $32.74 | $10.22 |
| Average True Range (ATR) | 0.62 | 0.62 |
| MACD | 0.06 | -0.15 |
| Stochastic Oscillator | 69.85 | 10.83 |
Stellar Bancorp Inc is a U.S. based bank holding company. Through its subsidiary, Stellar Bank, the company provides a diversified range of commercial banking services predominantly to small to medium sized businesses, professionals, and individual customers. Its offerings include different types of loans, such as mortgage loans, home equity loans, automobile loans, etc.; deposit products, such as checking accounts, commercial accounts, money market accounts, savings accounts, etc.; and other banking services like mobile banking, debit cards, cash management and wire transfer services, letters of credit, and others.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.